Compare AUB & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUB | KYMR |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.7B |
| IPO Year | N/A | 2020 |
| Metric | AUB | KYMR |
|---|---|---|
| Price | $34.82 | $86.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 19 |
| Target Price | $39.93 | ★ $69.58 |
| AVG Volume (30 Days) | ★ 1.0M | 1.0M |
| Earning Date | 01-22-2026 | 11-04-2025 |
| Dividend Yield | ★ 4.30% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $1,048,582,000.00 | $43,735,000.00 |
| Revenue This Year | $79.19 | $20.81 |
| Revenue Next Year | $14.11 | N/A |
| P/E Ratio | $19.62 | ★ N/A |
| Revenue Growth | ★ 41.48 | N/A |
| 52 Week Low | $22.85 | $19.45 |
| 52 Week High | $43.12 | $103.00 |
| Indicator | AUB | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 58.73 | 72.75 |
| Support Level | $33.94 | $64.84 |
| Resistance Level | $34.95 | $103.00 |
| Average True Range (ATR) | 0.88 | 4.10 |
| MACD | 0.23 | 2.09 |
| Stochastic Oscillator | 89.92 | 59.15 |
Atlantic Union Bankshares Corp is a financial holding company and a bank holding company. Through its community bank subsidiary, the company provides financial services, including banking, trust, and wealth management. The bank is a full-service community bank offering consumers and businesses a wide range of banking and related financial services, including checking, savings, certificates of deposit, and other depository services, as well as loans for commercial, industrial, residential mortgage, and consumer purposes. The company operates through two reportable operating segments: Wholesale Banking and Consumer Banking, with corporate support functions such as corporate treasury and others included in Corporate Other. It derives maximum revenue from Wholesale Banking.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.